EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Efferocytosis in liver disease

Hongxue Shi, Mary P Moore, Xiaobo Wang, Ira Tabas

JHEP Reports · 2024-01 · 6 (1) · 100960

DOI: 10.1016/j.jhepr.2023.100960 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JHEP Reports, 2024-01. Verfasst von Hongxue Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The process of dead cell clearance by phagocytic cells, called efferocytosis, prevents inflammatory cell necrosis and promotes resolution and repair. Defective efferocytosis contributes to the progression of numerous diseases in which cell death is prominent, including liver disease. Many gaps remain in our understanding of how hepatic macrophages carry out efferocytosis and how this process goes awry in various types of liver diseases. Thus far, studies have suggested that, upon liver injury, liver-resident Kupffer cells and infiltrating monocyte-derived macrophages clear dead cells, limit inflammation, and, through macrophage reprogramming, repair liver damage. However, in unusual settings, efferocytosis can promote liver disease. In this review, we will focus on efferocytosis in various types of acute and chronic liver diseases, including metabolic dysfunction-associated steatohepatitis. Understanding the mechanisms and consequences of efferocytosis by hepatic macrophages has the potential to shed new light on liver disease pathophysiology and to guide new treatment strategies to prevent disease progression.

Schlagwörter

Stichwörter der Autor:innen

Kupffer cellsacute liver injuryapoptotic cellshepatic stellate cellsliver fibrosisliver inflammationmacrophagesmetabolic dysfunction-associated steatohepatitis (MASH)tissue resolution

Autor:innen und Institutionen

  • Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY 10032, USA.

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Shi, H., Moore, M. P., Wang, X., & Tabas, I. (2024). Efferocytosis in liver disease. JHEP Reports, 6(1), 100960. https://doi.org/10.1016/j.jhepr.2023.100960

Vancouver

Shi H, Moore MP, Wang X, Tabas I. Efferocytosis in liver disease. JHEP Reports. 2024;6(1):100960. doi:10.1016/j.jhepr.2023.100960

BibTeX
@article{Shi2024,
  author = {Shi, Hongxue and Moore, Mary P and Wang, Xiaobo and Tabas, Ira},
  title = {Efferocytosis in liver disease},
  journal = {JHEP Reports},
  year = {2024},
  volume = {6},
  number = {1},
  pages = {100960},
  doi = {10.1016/j.jhepr.2023.100960}
}
Kostenlos starten →